EcoDrugPlus

Glycogen Synthase Kinase 3 Beta, Genome Duplicate A

Ensembl ID : ENSMAMG00000014811
Gene Symbol: GSK3BA
3 Cross references
222 Possible Orthologues:

Glycogen Synthase Kinase-3 Beta-Like

Ensembl ID : ENSMAMG00000008820
Gene Symbol: LOC113126211
3 Cross references
187 Possible Orthologues:

Gonadotropin Releasing Hormone Receptor 1

Ensembl ID : ENSMAMG00000014409
Gene Symbol: GNRHR1
2 Cross references
155 Possible Orthologues:

Granzyme B(G,h)-Like

Ensembl ID : ENSMAMG00000019144
Gene Symbol: LOC113129267
2 Cross references
988 Possible Orthologues:

Group 10 Secretory Phospholipase A2

Ensembl ID : ENSMAMG00000002302
Gene Symbol: ZGC:92162
3 Cross references
232 Possible Orthologues:

Growth Hormone Releasing Hormone Receptor, Like

Ensembl ID : ENSMAMG00000001828
Gene Symbol: GHRHRL
2 Cross references
191 Possible Orthologues:

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSMAMG00000027883
Gene Symbol: GHSRA
3 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSMAMG00000017928
Gene Symbol: GUCY1A1
3 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSMAMG00000006999
Gene Symbol: GUCY1A2
4 Cross references
202 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSMAMG00000017961
Gene Symbol: GUCY1B1
3 Cross references
210 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSMAMG00000013506
Gene Symbol: HSP90AA1.1
3 Cross references
330 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSMAMG00000004668
Gene Symbol: HSP90AB1
3 Cross references
339 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).